Strategic Financial Concepts LLC Purchases Shares of 119,236 GSK plc (NYSE:GSK)

Strategic Financial Concepts LLC bought a new position in shares of GSK plc (NYSE:GSK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 119,236 shares of the pharmaceutical company's stock, valued at approximately $4,033,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GSK. Indiana Trust & Investment Management Co lifted its position in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares during the last quarter. Eastern Bank bought a new position in shares of GSK during the 3rd quarter worth about $26,000. Crews Bank & Trust bought a new position in shares of GSK during the 4th quarter worth about $26,000. ST Germain D J Co. Inc. increased its holdings in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares during the period. Finally, Sunbelt Securities Inc. increased its holdings in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after purchasing an additional 302 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on GSK shares. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GSK presently has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Price Performance

NYSE GSK traded down $0.08 on Wednesday, reaching $36.54. The company's stock had a trading volume of 3,408,419 shares, compared to its average volume of 4,586,088. The firm has a market cap of $75.72 billion, a PE ratio of 22.98, a price-to-earnings-growth ratio of 1.11 and a beta of 0.64. The business has a 50-day moving average price of $34.49 and a 200 day moving average price of $37.38. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts expect that GSK plc will post 4.12 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.30%. GSK's payout ratio is 93.08%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.